Known as the brand name Lotrel, the combination of amlodipine besylate and benazepril is a powerful calcium channel blocker. The patent for this formidable medication marketed by Novartis expires on December 19, 2017, paving the way for a generic version of this blockbuster drug. With roughly one in three U.S. adults suffering from high blood pressure, this amounts to a staggering 68 million people. These numbers are expected to steadily rise over the next decade, especially with almost 30 percent of American adults currently diagnosed with prehypertension.
Side effects of amlodipine besylate as part of Lotrel are mild, and may include headache, cough, dizziness and swelling of the extremities. Amlodipine is effectual for the treatment of hypertension when dispensed in once-daily doses between 2.5 milligrams and 10 milligrams. The dosage of benazepril is offered in doses between 10 milligrams and 80 milligrams in the combination Lotrel pill. Patients can expect to notice positive results and a lowered blood pressure within two weeks of starting this medication. Results from six double-blind, placebo-controlled studies revealed great success for patients who were dosed with Lotrel. In over 950 patients who received Lotrel once daily participants recorded lowered blood pressure within 1 hour, with peak reductions in their blood pressure achieved 2-8 hours after dosing. Additionally, the antihypertensive effect of a single dose persisted for 24 hours for the vast majority of patients.
|Blood Pressure Levels|
|Normal||systolic: less than 120 mmHg
diastolic: less than 80mmHg
|At risk (prehypertension)||systolic: 120–139 mmHg
diastolic: 80–89 mmHg
|High||systolic: 140 mmHg or higher
diastolic: 90 mmHg or higher
The efficacious combination of amlodipine besylate and benazepril (Lotrel) helps to widen blood vessels in affected patients and improve blood flow. As an ACE inhibitor (angiotensin converting enzyme) this combination treatment for high blood pressure is greatly needed. Costs directly attributable to high blood pressure in the U.S. alone total almost $131 billion annually in direct medical expenses, as well as $25 billion in lost productivity.
LGM Pharma provides API amlodipine besylate, CAS number 111470-99-6 for your R&D needs. Clients can be assured of LGM Pharma’s continuous support throughout the research and development process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.